



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



CORRIGENDUM-1

Tender Reference No.: AIIMS/BLS/G/24-25/363/E-Ten/18

Tender enquiry No. : AIIMS/BLS/(G)/25-26/E-Tender/18

Tender Id : 2025_AMSBL_886796_1

Tender Name : Supply of drugs: (Tender for injections, patches, Respules, vaccines, MDI, suppositories, sachet, IV fluids, disinfectant and controlled substances.

1. (Extension of Bid Submission Date)

All prospective Bidders are hereby informed that the last date has extended of bid submission for above said tender as follows:

Particulars	Previous Date	Revised Date
Bid Submission End Date & Time	30/12/2025 at 15:00 Hours	10/01/2026 at 15:00 Hours
Bid Opening Date & Time	31/12/2025 at 15:00 Hours	12/01/2026 at 15:00 Hours

2. Amendments:

In this context, it is informed that following amendments/ changes have been made in tender document:

Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
Intas Pharma	List of requested products to be included	C1 esterase inhibitor 500 IU Vial	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence no change	No change
		Casposfungin acetate 50 mg Vial		
		Colistimethate Sodium 20,00,000 IU Vial (lyophilized inj.) Vial		
		Colistimethate Sodium 30,00,000 IU Vial (lyophilized inj.) Vial		
		Docetaxel Lipid Suspension 20 MG Inj. (Nanosomal) Vial		
		HUMAN PROTHROMBIN COMPLEX IP 250 IU CONCENTRATE Vial		
		Nanosomal Paclitaxel Lipid Suspension 100 mg vial		
		Nanosomal Paclitaxel Lipid Suspension 30 mg Vial		
		Romiplostim 500 mcg/1 mL vial (Lyophilised)		
		Romiplostim 125 mcg Vial		
		Tenecteplase 30 mg Injection		
		Trastuzumab 375 mg Vial		
Pertuzumab 420 MG vial				
Zydus life sciences	List of requested products to be included	Cocktail of two anti-rabies monoclonal antibodies (Docaravimab and Miromavimab) 1500 IU/2.5 ML	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence no change	No change
		Trastuzumab Emtansine 100 mg		
		Trastuzumab Emtansine 160 mg		
Zydus Healthcare	List of requested products to be included	Viscoelastic gel (PFS) 2 ml (Sodium Hyaluronate 20 mg + Sorbitol 40 mg.) per ml	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence no change	No change

36-8



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



सत्यमेव जयते

Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
Lupin ltd	Amendment requested in specification of item no. 1.370 i.e. Inj. Iron isomaltoside 1000 mg/ 10 ml	Inj. Iron isomaltoside 500 mg/ 5 ml	May be considered to encourage wider participation.	Item no. 1.370 may be read as Inj. Iron isomaltoside 500 mg/ 5 ml
Otsuka Pharma	Amendment requested in specification of item no. 1.018, Inj. Amino Acid 10%, Essential & non-essential amino acids with taurine 10%, 500 ml	Amino acid injection 10% with/ without electrolytes, 500 ml (Product is available with electrolytes)	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.018 deleted from the list
	Amendment requested in specification of item no. 1.023, Inj. Amino Acids Solution Intravenous 5 %/ 250 ml	Amino acid injection 5%, 200 ml/ 250 ml (200 ml amino acid available with sorbitol)	Said product is manufactured in India by various companies. Hence no change	No change
	Amendment requested in specification of item no. 1.636, Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamine E, Zinc, Electrolytes and Nitrogen ratio for central infusion 1400-1500 ml	TPN solution for central infusion, 1400-1500 ml (Product has all essential electrolytes included no extra supplementation needed & 20 all amino acids)	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.636 deleted from the list
	Amendment requested in specification of item no. 1.637, Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamin E, Zinc, Electrolytes and Nitrogen ratio for central infusion 900 – 1000 ml	TPN solution for central infusion, 900-1000 ml (Higher lipid content: product TNA 40 gm vs SMOF 38 gm & 20 all amino acids)	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.637 deleted from the list
	Amendment requested in specification of item no. 1.638, Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamin E, Zinc, Electrolytes and Nitrogen ratio for Peripheral infusion 1000-1250 ml	TPN solution for peripheral infusion, 1000-1250 ml (Product has higher calories: 0.76 kcal/ ml TNA vs 0.66 & 20 all amino acids)	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.638 deleted from the list
	Amendment requested in specification of item no. 1.639, Inj. TPN 3 Chambered Bag containing Amino Acid 10% with Taurine, 4 oil combined lipid emulsion soyabean oil, MCT, Olive Oil and Fish oil, Glucose, Vitamin E, Zinc, Electrolytes and Nitrogen ratio for Peripheral infusion 1400-1500 ml	TPN solution for peripheral infusion, 1400-1500 ml (Product is superior in terms of energy, protein and nitrogen provision per ml & 20 all amino acids)	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.639 deleted from the list
	List of requested products to be included	TPN solution for central infusion, 1400-1500 ml (Product has all essential electrolytes included no extra supplementation needed & 20 all amino acids)	To be published in upcoming tender with requirement from user department/ drugs formulary committee,	No change
		TPN solution for central infusion, 900-1000 ml (Higher lipid content: product TNA 40 gm vs SMOF 38 gm & 20 all amino acids)	To be published in upcoming tender with requirement from user department/ drugs formulary committee.	
		TPN solution for peripheral infusion, 1000-1250 ml (Product has higher calories: 0.76 kcal/ ml TNA vs 0.66 & 20 all amino acids)	To be published in upcoming tender with requirement from user department/ drugs formulary committee.	
		TPN solution for peripheral infusion, 1400-1500 ml (Product is superior in terms of energy, protein and nitrogen provision per ml & 20 all amino acids)	To be published in upcoming tender with requirement from user department/ drugs formulary committee.	



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimbilaspur.edu.in



Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
Fresenius kabi	List of requested products to be included	9 trace elements solutions for infusion 10 ml injection Paclitaxel nanoparticle inj. 100 mg/vial IV 0.9% Normal saline 100 ml in a closed system non-PVC bag sterilized at 121 degrees Celsius within overwrap with temper evident port IV 0.9% Normal saline 250 ml in a closed system non-PVC bag sterilized at 121 degrees Celsius within overwrap with temper evident port IV 0.9% Normal saline 500 ml in a closed system non-PVC bag sterilized at 121 degrees Celsius within overwrap with temper evident port IV 0.9% Normal saline 1000 ml in a closed system non-PVC bag sterilized at 121 degrees Celsius within overwrap with temper evident port IV dextrose 5% 500 ml in closed system non-PVC bags sterilized at 121 degrees Celsius within overwrap with temper evident port IV dextrose 5% and 0.9% normal saline 500 ml in closed system non-PVC bags sterilized at 121 degrees Celsius within overwrap with temper evident port IV Multi electrolyte solution 250 ml in closed system non-PVC bags sterilized at 121 degrees Celsius within overwrap with temper evident port IV Multi electrolyte solution 500 ml in closed system non-PVC bags sterilized at 121 degrees Celsius within overwrap with temper evident port IV Multi electrolyte solution 1000 ml in closed system non-PVC bags sterilized at 121 degrees Celsius within overwrap with temper evident port 6% hydroxy ethyl starch with plasma adapted solution having acetate as buffering agent in non-PVC closed system bags sterilized at 121 degrees Celsius within overwrap 6% hydroxy ethyl starch in normal saline in non-PVC closed system bags sterilized at 121 degrees Celsius within overwrap Inj paracetamol 1 gm/ 100 ml in a closed system non-PVC bag sterilized at 121 degrees Celsius within overwrap with temper evident ports	To be published in upcoming tender with requirement from user department/ drugs formulary committee.	No change
	Amendment requested in specification of item no. 1.374	Isotonic solution-IVF multiple electrolyte specification includes only single company product	May be amended with revised specifications	Item no. 1.374 may be read as "Multiple electrolytes injection for IV administration" 500 ml bag



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



सत्यमेव जयते

Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
Fresenius kabi	requested products to be included	Bag demand is there in AIIMS for fluids PN, PCM, HES 6% and NS 250 ml free flex bags but only bottles are there	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence No change	No change
	requested products to be included	We are providing 4 oil combinations as a unique TPN 3 chambered bag based on German technology brand.		
	requested products to be included	Unique 9 trace elements injections addaven injection, we are only company providing this 9 combinations trace element injection		
	requested products to be included	For weekly regimen for "nanoparticle paclitaxel 100 mg"		
Boehringer Ingelheim	Amendment requested in specification of item no. 1.014	Correction of strength of injection Alteplase from 2 mg to 20 mg, as 2 mg strength not available.	May be amended as Alteplase 20 mg.	Item no. 1.014 may be read as injection Alteplase 20 mg
GE healthcare	Amendment requested in delivery period in case of emergency (Page no.-22, point no. 10.9)	As we are importer, we request that the emergency delivery period be modified to 30 days instead of 15 days.	To meet the urgent situation/ critically ill patients, minimum delivery time may be considered, hence No Change.	No change
	Amendment requested in specification of item no. 1.360 i.e. Inj. Iodixanol Injection USP 755 mg or 350 mg/ml, 100 ml	Request to amend it as Inj. Iodixanol Injection 320 mg I/ ml, 100 ml	May be amended to 320 mg I /ml, 100 ml, as per comments received from user department.	Item no. 1.360 may be read as Injection Iodixanol USP 320 mg I/ ml, 100 ml.
Vaishali enterprises	Pre bid date 03.12.2025	Request to provide pre bid submission up to next Monday i.e. 08.12.2025 to thoroughly read tender document	Not Considered, sufficient time given for thoroughly read the tender, hence No Change.	No change
Sam Pharma com.	Pre bid date 03.12.2025	Request to provide 3-4 days for pre bid submission to thoroughly read tender document	Not Considered, sufficient time given for thoroughly read the tender, hence No Change.	No change
	Products Manufactured by OEM through third party/loan license will be considered. But only OEM (marketer) will participate in the tender.	Requested to remove this clause	To maintain uninterrupted supply not Considered, hence No Change.	
MSN lab	Sole manufacturer	Detail of documents required	As per GFR	No change
	AIIMS supply not for sale	For small quantities AIIMS supply or govt. supply may be accepted	AIIMS Bilaspur Supply/ AIIMS Supply/ Govt. Supply, not for sale (may be considered in urgent cases or in case of small quantities)	May be read as AIIMS Bilaspur Supply/ AIIMS Supply/ Govt. Supply, not for sale (may be considered in urgent cases or in case of small quantities)
	PBG	Amended PBG to 3%	Not considered, hence No Change.	No change
	Sampling clause	Sampling clause for dyes must be there (Used for CT, MRI and PET scan)	Kindly refer point no. 1 at page number 15 and point no 24 at page no. 29 of tender document, hence no change	No change
	PAC certificate	Elaborate PAC certificate and other documents required for PAC items	The detail not mentioned by representative, hence no change	No change
Celon Labs	requested products to be included	Injection Palonosetron 75 mcg/ 1.5 ml	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence No change	No change
Zymes biosciences	List of requested products to be included	Meropenem 1g + Sulbactam 1g Meropenem 1g + Sulbactam 2g Cefepime 1g+ Tazobactam 1g Glutathione 1200 mg Glutathione 2000 mg Micafungin 150mg Ceftazidime 1g + Avibactam 500 mg	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence No change.	No change



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aaimsbilaspur.edu.in



Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
Zymes biosciences	List of requested products to be included	Ceftazidime 1g + Avibactam 250 mg Avibactam 500mg Doripenem 1g Doripenem 500mg + Sulbactam 500 mg Aztreonam 1g + Avibactam 250 mg Ademetionine 400 mg	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence No change.	No change
Takeda Bio pharmaceutical	<p>“CERTIFICATE OF PRICE JUSTIFICATION” Quote “Certify that the rates provided are our best rates and we have not given these materials to any Government Department/PSU/Institution for lesser than these rates in last financial year. I/We also certify that the discount offered is not lower than those offer to DGS&D and other government departments and shall not offer higher discount than the quoted one during the period of contract to any other government organization.” Unquote</p> <p>2. Shelf-Life: For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture. For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture. For all those drugs, which are required to be stored under controlled temperature / cold chain, have to be supplied under controlled temperature/cold chain. If the supplied item is not utilized before expiry date the supplier should undertake to replace with fresh stock of items as and when required. The supplier shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.</p>	<p>With reference to the "Manual for Procurement of Goods" dated June 2022, issued by the Government of India, Ministry of Finance, Department of Expenditure, and office memorandum number 31026/1/2019-Policy Dated 12.11.2020 of GOI states we would like to draw your attention to a specific provision as outlined in page 143, under clause 8.1.14. <u>It is explicitly mentioned that the fall clause does not apply to the sale of drugs that have an expiry date.</u> For your ease of reference, we have attached the relevant page of this manual. <u>Considering this provision, we kindly request the removal of the fall clause/Rate Certificate from the above-mentioned tender. Your cooperation in this matter would be greatly appreciated</u></p> <p>We would like to put across our request that our product is exclusively imported from overseas i.e. from USA & Europe GMP approved manufacturing plants and has a lead time of 5 to 6 months for manufacturing, testing at plant site followed by importation. Further in-country. Testing and custom clearance takes another 60 days (approx.) to complete before product is made available for commercial use. Seeing the exclusivity of the product and to keep the continuity of the supplies of the medicines to the patients of rare disease even Institutes like DHS Tripura, CPA Delhi, ESIC Delhi, ESIS Karnataka, AMSCL, CGHS etc. has granted permission to supply imported products with 50% shelf life. (<i>Attachment-1 tender clauses of these institutes</i>). Also, there are institutes who consider shelf life even below 50% but with an “Undertaking Letter” stating, “the product will be replaced if not consumed”. Undertaking by the supplying firms to replace the goods if not</p>	<p>May be considered, amendment may be issued, as per provision of GFR.</p> <p>May be amended as, “up to 50% of shelf life remains at the time of delivery” with undertaking to replace the item within 15 days of intimation.</p>	<p>“Certificate of price justification” section-xx at page no. 44 of tender document deleted</p> <p>Page no. 25 point no. 2. Shelf Life may be read as, “up to 50% of shelf life remains at the time of delivery” with undertaking to replace the item within 15 days of intimation.</p>

364



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure drug@aiimsbilaspur.edu.in



		consumed is an assurance for the purchaser for any monetary loss. <u>Kindly consider our request to accept stocks with 50% shelf life for imported products with an undertaking of product replacement.</u>		
	Sl. No. 1.316 Inj. Human Albumin 5% 5 gm/100ml	We wish to inform you that our product, HUMAN ALBUMIN 5% is available in 250 ml pack size. We kindly request you to add or amend the pack size 250 ml as per below specification. "Human Albumin Solution IP 5% 250 ml"	Available mostly in 100 ml, hence no change	No change
	Sl. No. 1.315 to 1.318 Inj. Human Albumin 20% 20 gm/100 ml	We wish to inform you that our product, HUMAN ALBUMIN 20% 100ML INJ is offered in India with two different packaging options : one in bottles and the other in bags, ensuring consistent product efficacy across both. We kindly request an update to the tender specifications to specify "HUMAN ALBUMIN 20% 100ML INJ" with pack size of Bottle/Bag .' This adjustment will allow us to supply either bottles or bags based on current availability, ensuring uninterrupted patient care.	May be amended to "bottle" for unit of measurement, as it is supplied generally in bottle instead of vial.	For item at serial no. 1.315, 1.316, 1.317 and 1.318 the unit of measurement may be read as "Bottle"
Unijules life sciences	Amendment requested in specification of item no. 1.360 i.e. Inj. Iodixanol Injection USP 755 mg or 350 mg/ml, 100 ml	Kindly clarify product strength, as its mostly available in 320 mg/ ml, kindly amend it as 652 mg or 350 mg/ml	May be amended to 320 mg l/ ml, 100 ml.	Item no. 1.360 may be read as Injection Iodixanol USP 320 mg l/ ml, 100 ml.
	Amendment requested in specification of item no. 1.190 i.e. Inj. Diatrizoate meglumine and diatrizoate sodium Injection USP 370 mg/ml, or 76%, 30 ml	Request to amend it as "100 ml vial"	Not considered as per comments received from user department, hence no change.	No change
NANZ MEDSCIE NCE PHARMA	Amendment requested in specification of item no. 1.686 Benzalkonium chloride 0.5% 500 ml	It would be 5% v/v instead of 0.5%. The complete specification as under: - BENZALKONIUM CHLORIDE LIQUID Composition: Benzalkonium Chloride Solution IP 5%v/v Colour: Tartrazine	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.686 deleted from the list
	Amendment requested in specification of item no. 1.693 Chloroxylenol 4.8% w/v 500 ml	Complete specification not mentioned in the Tender Enquiry. It would be as under: - CHLOROXYLENOL, TERPINEOL & ABSOLUTE ALCOHOL LIQUID Contains: Chloroxylenol IP 4.8 % w/v Terpineol BP 9% v/v Absolute Alcohol (Denatured) 13.1%	The said product is under review, to be published in upcoming tender with requirement from user department/ drugs formulary committee, hence deleted from the list	Item no. 1.693 deleted from the list



363

Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
	Amendment requested in specification of item no 1.723 Ethanol 70% w/v 500 ml	Only Ethanol mentioned. We are giving below the combination specification if required. CHLORHEXIDINE GLUCONATE & ETHANOL LIQUID Contains: Chlorhexidine Gluconate Solution IP 10% v/v (Eq. to Chlorhexidine Gluconate 2% w/v) Ethanol IP 70% v/v Aqueous base q.s. Approved Colours Used	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.725 Ethanol, 2-propanol (isopropanol), and 1-propanol 5 litre	It would be as under: - ETHANOL, 2 PROPANOL & 1 PROPANOL LIQUID Each 100 gm Contains: Ethanol IP 10 gm 2- Propanol IP 9 gm 1- Propanol BP 6 gm Aqueous base q.s. As far as packing is concerned, the regular packing is 500ml instead of 5 Litre	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.726 Ethanol, 2-propanol (isopropanol), and 1-propanol 250 ml with spray	It would be as under: - ETHANOL, 2 PROPANOL & 1 PROPANOL LIQUID Each 100 gm Contains: Ethanol IP 10 gm 2- Propanol IP 9 gm 1- Propanol BP 6 gm Aqueous base q.s.	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.736 and 1.737 Isopropyl alcohol-based hand sanitizer 70% w/v 5Litre and Isopropyl alcohol-based hand sanitizer with pump 70% w/v 500 ml	Only Isopropyl alcohol mentioned. There are two specifications, which cover Isopropyl Alcohol. CHLORHEXIDINE GLUCONATE & ISO-PROPYL ALCOHOL LIQUID Contains: Chlorhexidine Gluconate Solution IP 2.5% v/v (Eq. to Chlorhexidine Gluconate 0.5% w/v) Iso Propyl Alcohol IP 70% v/v Aqueous base q.s.	Not considered, hence no change	No change

362



Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



सत्यमेव जयते

		Approved Colours Used OR 2 PROPANOL, 1 PROPANOL & ETHYL-HEXADECYL-DIMETHYL AMMONIUM ETHYLSULPHATE LIQUID Each 100 gms Contains: 2-Propanol I.P. 45 gms 1-Propanol B.P 30 gms Ethyl-hexadecyl-Dimethyl-Ammonium-Ethylsulphate 0.2 gms Approved colour used.		
	Amendment requested in specification of item no 1.778 Surgical spirit IP 5 Liters	Complete specification not mentioned. It would be as under: - SURGICAL SPIRIT IP Methyl Salicylate IP 0.5% v/v Diethyl Phthalate IP 2% v/v Castor Oil IP 2.5% v/v Industrial Methylated Spirit IP q.s.	May be amended to "surgical spirit IP for medical use 5 liters only"	item no 1.778 may be read as " surgical spirit IP for medical use only, 5 liters "
	Amendment requested in specification of item no 1.779 Surgical spirit IP 500 ml	Complete specification not mentioned. It would be as under: - SURGICAL SPIRIT IP Methyl Salicylate IP 0.5% v/v Diethyl Phthalate IP 2% v/v Castor Oil IP 2.5% v/v Industrial Methylated Spirit IP q.s.	May be amended to "surgical spirit IP 500 ml for medical use only"	item no 1.779 may be read as " surgical spirit IP for medical use only, 500 ml "
	Regarding Manufacturing and Marketing Certificate	three-year Manufacturing and Marketing Certificate (MMC) for narcotic medicines be relaxed or removed.	May be relaxed to 1 year only in case of items at serial number 1.783 to 1.787 (Fentanyl patches)	Point no. 2 at page no. 27 of tender document may be read as scanned copy of manufacturing and marketing standing/ experience certificate of minimum 1 year of the molecule quoted by them" in case of items at serial number 1.783, 1.784, 1.785, 1.786 and 1.787 (Fentanyl patches) only.
Verve human care	Amendment requested in specification of item no 1.783 Fentanyl Patch 12.5 mcg/hr.	Fentanyl Transdermal System Patch 12 OR 12.5 mcg/hr (Net Content: Not less than 2 mg) 12 mcg/hr and 12.5 mcg/hr patches deliver the same net content of fentanyl over 72 hours.	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.784 Fentanyl Patch 25 mcg/hr	Fentanyl Transdermal System Patch 25 mcg/hr (Net Content: Not less than 4 mg)	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.785 Fentanyl Patch 50 mcg/hr	Fentanyl Transdermal System Patch 50 mcg/hr (Net Content: Not less than 8 mg)	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.786 Fentanyl Patch 75 mcg/hr	Fentanyl Transdermal System Patch 75 mcg/hr (Net Content: Not less than 12 mg)	Not considered, hence no change	No change
	Amendment requested in specification of item no 1.787 Fentanyl Patch 100 mcg/hr	Fentanyl Transdermal System Patch 100 mcg/hr (Net Content: Not less than 16 mg)	Not considered, hence no change	No change



361

Procurement Section
All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575
E-mail: procure_drug@aiimsbilaspur.edu.in



Name of company	Issue highlighted	Suggestion received/ proposed specification	Draft reply	Amendment/ may be read as
OPI/ RICA enterprises	Turn over	Turnover to be revised to 25 crores from 35 crores	Not considered, hence no change	No change
Astrazeneca	requested products to be included	a) Injection Durvalumab 120mg/ 2.4 ml b) Injection Durvalumab 500 mg/ 10 ml c) Tablet Osimertinib 80 mg d) Trastuzumab deruxtecan infusion 100 mg/ vial e) Tremelimumab concentrate solution for infusion 300 mg/ 15 ml f) Injection Goserelin acetate 3.6 mg	May be considered for upcoming tender with requirement from user department/ drugs formulary committee. Hence No change.	No change
Neon Lab. Ltd.	Amendment requested in point no. 10.18 (11) page no.-20 i.e. MRP should not be written/embossed/should be defaced with indelible ink on any labels otherwise it will be disqualified for that supply.	We cannot deface the MRP but on the same stock we will stamp it as "AIIMS supply not for sale" because if MRP to be inked then we have to break the blister.	MRP must be masked on blister packing, may be relaxed to mask on ampoule in case of auto packing of ampoules.	Point no. 10.18 (11) page no.-20 may be read as "MRP must be masked on blister packing and may be relaxed to mask on ampoule in case of auto packing of ampoules in blister".
	Rates should be quoted for strip packing only except where mentioned.	Unit rate must be quoted	May be amended as "Unit rate must be quoted in financial bid & pack size of primary & Secondary pack mentioned in technical bid (Rates should not be quoted in technical bid)	Point no. 10.18 (4) at page no. 20 may be read as "unit rate must be quoted"
Alkem Laboratories	Request separate bidding for item no. 1.179 Denosumab 60 mg	Allowing separate bidding for Denosumab 60 mg which permit mg-based (weight/volume) justification instead of mandatory quoting of both strengths, OR Provide guidance on how our mg-based clinical usage can be appropriately represented within the current tender evaluation framework	May be amended for separate bidding in case of item number 1.179 and 1.180. Also, specifications of item number 1.180 may be amended as Injection Denosumab 120 mg/ 1.7 ml vial instead of PFS.	For item no. 1.179 and 1.180 separate quote/ bid may be considered and evaluation shall be done individually for each item on the basis of individual item rate.
	Request separate bidding for item no. 1.132 Cetuximab 100 mg	Allowing separate bidding for Cetuximab 100 mg which permit mg-based (weight/volume) justification instead of mandatory quoting of both strengths, OR Provide guidance on how our mg-based clinical usage can be appropriately represented within the current tender evaluation framework	Not considered, hence no change	No change Also reply as per "#"

"#" We are in receipt of your representation suggesting a modification to the financial bid structure to allow quoting on a "per milligram" basis rather than per individual SKU (100mg and 500mg).

After a detailed review by committee, we cannot accept this suggestion. The requirement to quote for both the 100mg and 500mg strength remains unchanged on the basis of following deliberations:

1. Costing and Inventory Variance

We are aware that the manufacturing and packaging overheads for a 100mg vial differ significantly from a 500mg vial. A flat "per mg" rate implies a linear cost structure that does not exist in reality. Furthermore, our inventory management system requires tracking by specific SKU (Unit) rather than total bulk volume.

2. Prevention of Drug Wastage (Financial Implication)



Procurement Section

All India Institute of Medical Sciences, Bilaspur (H. P.), Phones: 01978-292575

E-mail: procure_drug@aiimsbilaspur.edu.in



Cetuximab is a high-value biological drug. Our procurement strategy is designed to minimize wastage based on patient Body Surface Area (BSA)/ Body weight requirements.

- **Example:** If a patient requires a dose of **600mg**, the protocol is to open one 500mg vial and one 100mg vial.
- If the tender is evaluated on a generic per-mg basis, it may incentivize the supply of only larger vials. In the scenario above, if we are forced to open two 500mg vials to achieve a 600mg dose, **400mg of the drug would be wasted/discarded.**
- Given the high cost of the drug and the short stability period after opening, this wastage is financially unacceptable.

3. Clinical Compatibility and Patient Safety (Crucial)


To ensure patient safety, it is mandatory that the different vial strengths used for a single patient belong to the same manufacturer.

- **No Mixing Allowed:** Mixing a 500mg vial from manufacturer A with a 100mg vial from manufacturer B in the same infusion bag can lead to physicochemical incompatibility and increased immunogenicity risks (due to difference in their additive may be).
- **Single Source Requirement:** Therefore, we cannot split the both strengths between manufacturers. A single manufacturer must be awarded both items to ensure that a patient requiring a combination dose receives the exact same molecule formulation and minimize the adverse reactions and maximize the patient safety.

Conclusion To ensure zero wastage and strict adherence to clinical safety protocols regarding brand mixing, manufacturers are mandatorily required to quote for both line items (100mg and 500mg).

Failure to quote for both items will result in the bid being treated as non-responsive and liable for rejection.

“The other terms and conditions of the tender shall remain same”.


**Faculty In-charge
Procurement)
AIIMS, Bilaspur**

Email ID: procure_drug@aiimsbilaspur.edu.in